Lv5
1320 积分 2025-05-06 加入
Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
4天前
已完结
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
4天前
已完结
Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysis
11天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
15天前
已完结
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
15天前
已完结
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
15天前
已完结
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
15天前
已完结
304P Sintilimab consolidation therapy following concurrent chemoradiotherapy in unresectable stage III NSCLC: Primary results from the prospective CONSIST trial
23天前
已关闭
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
24天前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
28天前
已完结
皖公网安备34019202002308
